DUBLIN, Oct. 2, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as atherosclerosis and stroke. The normal physiological range of total blood cholesterol is 140-200 mg/dL. However, blood cholesterol consists of various individual components such as LDL cholesterol and HDL cholesterol. While LDL delivers cholesterol to the body, HDL removes cholesterol from cells by reverse cholesterol transport to the liver.
Owing to their distinct roles, these components are separately taken into account to determine the dyslipidemic status of an individual. The inheritable form of hypercholesterolemia, characterized by elevated total cholesterol and LDL cholesterol levels, is known as familial hypercholesterolemia. When the condition is inherited due to the presence of one abnormal copy of the LDL receptor gene, it is known as heterozygous familial hypercholesterolemia. The presence of abnormal copies of both the LDL receptor alleles leads to homozygous familial hypercholesterolemia.
The analysts forecast the Global Hypercholesterolemia market will grow at a CAGR of 3.81 percent over the period 2014-2018.
This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The report, the Global Hypercholesterolemia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hypercholesterolemia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Clinical Pipeline Portfolio
08. Market Segmentation by Type of Disease
09. Market Segmentation by MOA
10. Global Statins Market
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
Companies Mentioned:
- AbbVie Inc.
- Aegerion Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Astrazeneca PLC
- AtheroNova Inc.
- Biospherics.net Incorporated
- Bristol-Myers Squibb Company
- Catabasis Pharmaceuticals Inc.
- Cerenis Therapeutics
- CymaBay Therapeutics
- Daiichi Sankyo Inc.
- Eli Lilly and Company
- Esperion Therapeutics Inc.
- Glaxosmithkline plc
- Kadmon Pharmaceuticals LLC
- Kowa Pharmaceuticals America Inc.
- Laboratoires SMB S.A.
- Madrigal Pharmaceuticals Inc.
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- REGENX BioSciences
- Regeneron Pharmaceuticals Inc.
- SA
- Santaris Pharma A/S
- Serometrix LLC
- Shionogi Pharma Inc.
- Spherix Incorporated
- Sun Pharma USA
- Tekmira Pharmaceuticals Corp.
For more information visit http://www.researchandmarkets.com/research/hzdz85/global
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
